MA-BRIGHTCOVE
5.3.2024 15:04:33 CET | Business Wire | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced it is welcoming MotoAmerica, North America’s premier motorcycle road race series, to its roster of media customers. As the official streaming provider for MotoAmerica, Brightcove will power the live and video-on-demand (VOD) capabilities of the MotoAmerica Live+ streaming service, which will exclusively broadcast the upcoming 82nd running of the Daytona 200 (March 7-9, 2024).
“Delivering quality live and on-demand streaming experiences is essential for today’s sports and entertainment organizations to reach and engage their audiences effectively,” said Marc DeBevoise, CEO of Brightcove. “We’re happy to partner with MotoAmerica to help them deliver a unique viewing experience for fans worldwide. Through our award-winning platform, MotoAmerica will now be able to monetize its content on a global scale and drive additional revenue.”
“MotoAmerica began the journey into live-streaming motorcycle racing events in 2019. Throughout the years, we’ve received feedback from our fans to enhance the viewing experience,” said MotoAmerica COO Chuck Aksland. “In response, we decided to collaborate with Brightcove to offer our fans the upgraded experience they have been asking for. With the new platform provided by Brightcove, MotoAmerica can incorporate additional elements into the overall viewing experience. These elements include integrated live timing, betting options, news updates, merchandise offerings, and access to the 24-hour all-motorsports channel MTRSPT1, all in one location. Partnering with Brightcove ensures that both current and new fans of MotoAmerica can enjoy the best viewing experience possible. We are very excited about the improvements and are confident that our fans will appreciate the enhanced features and functionality now available to them.”
To tune in to MotoAmerica's action, fans can subscribe to MotoAmerica’s live streaming service, MotoAmerica Live+. Subscribers can watch races in all MotoAmerica classes live or on-demand and view highlights, interviews, and races from years past.
MotoAmerica joins a roster of professional sports organizations currently deploying Brightcove’s technology to connect with their fans, including Atlantic Coast Conference (ACC) Raycom Sports, ATP Tour, Badminton Horse Trials, Canadian Football League, Confederation of North, Central America and Caribbean Association Football (Concacaf), Harness Racing Victoria, Little League Baseball and Softball, Major League Soccer (MLS), National Hockey League (NHL), National Hot Rod Association (NHRA), U.S. Ski & Snowboard, United States Olympic and Paralympic Committee, United World Wrestling and USA Volleyball.
The addition of MotoAmerica further demonstrates Brightcove as the world’s leading streaming technology partner with a reliable, scalable, and flexible platform trusted by some of the most prominent sports entities in the world.
For more information, visit Brightcove.com.
About MotoAmerica
MotoAmerica is North America’s premier motorcycle road racing series. Established in 2014, MotoAmerica is home to the AMA Superbike Championship as well as additional classes, including Supersport, Stock 1000, Twins Cup, Junior Cup, and King Of The Baggers. MotoAmerica is an affiliate of KRAVE Group LLC, a partnership including three-time 500cc World Champion, two-time AMA Superbike Champion, and AMA Hall of Famer Wayne Rainey; ex-racer and former manager of Team Roberts Chuck Aksland; motorsports marketing executive Terry Karges; and businessman Richard Varner. For more information, please visit www.MotoAmerica.com and follow MotoAmerica on Facebook, Instagram, TikTok, Twitter, and YouTube.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X (Formerly Twitter), Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305118283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom